-
2024-514917-36-00
5
2024-11-21
Patients with High Risk Neuroblastoma
-
2023-504508-26-00
6
2024-11-14
Spinal Muscular Atrophy (SMA)
-
2023-507178-41-00
9
2024-11-07
Hematologic Malignancies or Solid Tumors in Pediatric and Young Adults
-
2023-509340-10-00
5
2024-10-29
Patients with HLA-A2 positive phenotype and metastatic Non-Small Cell
-
2024-511319-91-00
5
2024-10-23
Advanced non-small cell lung cancer with HER2 (ERBB2) mutation
-
2023-510429-14-00
4
2024-10-22
HER2-mutated or overexpressed/amplified solid tumours
-
2023-508581-15-00
5
2024-10-08
Heart condition
-
2024-514304-14-00
1
2024-10-08
Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
-
2023-506613-22-00
5
2024-09-25
coronary artery disease
-
2024-513087-26-00
5
2024-09-10
Metastatic Non-small Cell Lung Cancer
-
2023-506503-26-00
5
2024-07-31
Polyneuropathy, Inflammatory Demyelinating, Chronic
-
2022-502629-16-00
5
2024-07-10
Hemolytic Disease of the Fetus and Newborn (HDFN)
-
2023-508613-17-00
5
2024-05-29
Neoplasms, Head and Neck
-
2023-506308-24-00
10
2024-05-22
Recurrent or metastatic head and neck squamous cell carcinoma
-
2023-503631-18-01
5
2024-05-20
Nervous system diseases
-
2022-503142-41-00
5
2024-05-06
Mucopolysaccharidosis type II
-
2023-503865-48-00
4
2024-02-16
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
-
2022-502332-39-00
4
2023-11-15
Tuberous sclerosis complex (TSC)
-
2023-503582-35-00
6
2023-10-26
Staphylococcus aureus bacteremia
-
2023-503558-10-00
5
2023-10-13
oligometastatic pancreatic cancer
-
2022-503133-54-00
7
2023-08-09
Solid Tumors
-
2022-500967-11-00
5
2023-07-06
Previously Untreated Metastatic or Unresectable Melanoma
-
2022-501187-18-00
5
2023-04-24
a. Diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS)
-
2022-500783-35-00
5
2022-12-06
Acute Myeloid Leukemia